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The historical legacy of zoonotic viral diseases includes more than 50 million
human deaths (3% of the world’s population) due to the appearance of a
novel influenza virus in the early 1900s as well as the emergence of
previously unknown diseases such as hantavirus pulmonary syndrome in
1993 [1] and severe acute respiratory syndrome (SARS) in 2003 [2]. Pre-
venting epidemics resulting from other emerging viral diseases, whether due
to ordinary interactions of humans and animals, to man-made environmental
changes, or even to increased exposure following natural disasters such as
earthquakes or tsunamis, depends on the harmonization of all aspects of
animal and human health. This recognition of the inextricable interplay
between animal and human diseases led to the development of the ‘one
health’ concept, which aims to foster synergistic relationships that promote
the wellbeing of both animals and humans [3].
Vaccination is generally a very effective way to control the spread of viruses
among and between animals and humans. Although for some viruses such as
hantaviruses, which are carried by persistently infected rodents, it would be
very difficult to prevent human infections by vaccinating the natural host, for
other viruses, interrupting the infection of animals could prevent human
disease. One of the best-studied examples of this strategy is rabies vaccina-
tion of animals. As described by Briggs, great strides in controlling wild-life
rabies have been made since the advent of new generations of rabies
vaccines including recombinant vector-based vaccines. Despite this accom-
plishment, and despite the existence of vaccines that are 100% effective in
preventing human disease, more than 50,000 people worldwide die from
rabies each year, most of whom contracted infections from dogs. As the
author indicates, a coordinated approach including epidemiological studies,
pre-exposure vaccination of humans and dogs in addition to the established
post-exposure vaccination regimens is crucial for preventing these human
deaths, and she suggests that this effort could be enhanced by including a
contraceptive in the vaccines to reduce dog populations in areas where rabies
is prevalent.
Another example of vaccinating animals to prevent human disease is
described by Bird and Nichol for Rift Valley fever virus (RVFV) in Africa.
RVFV is transmitted from infected livestock, such as cattle and sheep, to
humans by mosquito bite or by contact with infected animal tissues. Disease
in humans is generally self-limiting although a small percentage of people
develop hemorrhagic fever or acute retinitis leading to blindness. Drought
resistant mosquito eggs can harbor the virus for long periods of time, and
when heavy rainfall occurs, mosquitoes carrying RVFV flourish, resulting in
a new epidemic cycle of RVF in susceptible animals, with eventual spillover
to humans [4]. With the development of reverse genetics systems for
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producing live-attenuated RVFV vaccines, it is now
possible to tailor vaccines for maximum efficacy without
reversion to virulence. These modern vaccines, along
with mosquito control measures, offer the promise of
eliminating the explosive outbreaks of disease associated
with this virus that have occurred in the past.
Fausther-Bovendo, Mulangu and Sullivan address issues
associated with vaccination against another hemorrhagic
fever virus, Ebola virus (EBOV), which causes disease in
humans and non-human primates in Africa. The authors
detail the complexities of developing a vaccine against a
very high consequence pathogen of uncertain etiology
that appears only sporadically. Evidence points toward
bats as a natural reservoir of EBOV, but efforts are still
underway to confirm and define the host and virus associ-
ations. Even with such information, it would be highly
impractical to attempt vaccinating bats to prevent in-
fection of humans and nonhuman primates because so
little is known about the life cycles of the many different
species of bats in EBOV endemic regions. Thus, the most
likely targets of an EBOV vaccine are at risk laboratory
workers and individuals in areas where an epidemic is
occurring. In addition, because EBOV and related filo-
viruses are considered to be biological warfare or bioter-
rorism threats, efforts have been made to develop a
vaccine that could be stockpiled for use in such events.
An another vaccine target population is endangered great
apes, which appear to be as susceptible to EBOV disease
as humans. To date, several vaccine candidates against
EBOV have shown promise in laboratory studies,
although none have yet progressed toward licensure. As
licensure will depend on studies conducted under the
Food and Drug Administration’s ‘Animal Rule’ which is
described in the paper by Burns, reliable animal models
must also be developed.
Eradication of viral diseases through vaccination has been
the ultimate quest of virologists since smallpox was
declared to no longer exist in nature in 1980 [5,6]. Enthu-
siasm for similar victories has dampened since then, as it
has proven to be extremely difficult to eradicate most viral
diseases, even those such as poliovirus, which like small-
pox virus, is an exclusive human pathogen. Remarkably,
the second virus to be eradicated after smallpox was a
veterinary pathogen, rinderpest virus, a devastating dis-
ease of cattle that has indirectly affected human health by
causing famines. This example offers hope and important
lessons to be learned for similar successes with related
human viruses such as the closely related measles virus.
De Swart, Duprex and Osterhaus describe the successful
eradication of rinderpest virus (RPV) in 2011 and inves-
tigate parallels and differences to the situation around
eradication of measles virus. Both viruses are highly
species restricted; thus, strategies similar to those used
against RPV might also be useful for measles eradication.
The authors point out, however, that eradication of RPV
was enabled by the availability of a temperature-stable,
live-attenuated vaccine, and the ability to stop mass
vaccination to track remaining pockets of viral infection,
which were then eliminated by targeted vaccination and
culling of animals. The measles vaccine currently used
still requires a cold chain and general mass vaccination
will have to be maintained until the virus is eradicated in
all parts of the world due to the danger of re-introducing
the virus into naı¨ve populations by international travel.
The authors further discuss the possibility that one of the
many viruses similar to RPV already present in animals,
such as canine distemper virus, could evolve to jump
species and fill the niche vacated by RPV.
The emergence of animal viruses as human pathogens in
the wake of eradication is further discussed by Reynolds,
Carroll and Karem, who compares facets of human mon-
keypox to smallpox. Because vaccination of humans
against smallpox also prevented them from developing
monkeypox, the eradication of smallpox along with ces-
sation of smallpox vaccinations has resulted in the appear-
ance of monkeypox in susceptible humans. As she
describes, however, there are several natural barriers
for monkeypox to become widespread in humans without
significant evolutionary changes that would increase
human-to-human transmission.
In addition to emergence of animal viruses to fill
ecological niches vacated by eradicated human patho-
gens, it is also possible for viruses to emerge due to
species jumping events. Such events have become
increasingly apparent as new tools for identifying novel
viruses in wildlife have been developed. Delwart
describes the potential for using these new molecular
methods for biosurveillance and detection of new
viruses and discusses the evidence for cross-species
transmission events for a number of viral families. Such
studies underline the importance of continuous surveil-
lance and coordination of animal and human health
efforts as is the goal of the one health initiative. Many
previously unknown viruses have been identified in-
cluding new viruses infecting humans; however, studies
to correlate these viruses with specific clinical manifes-
tations largely remain to be conducted. Nevertheless,
knowledge of their existence is likely to speed any
future efforts at vaccine development in the event that
a pathogenic link is discovered.
A final and important interface between animal and
human vaccines is the use of animal models for licensure
of human vaccines for which it is impossible or unethical
to use humans for efficacy testing. Burns describes regu-
latory aspects of the U.S. Food and Drug Administration
(FDA) rule, 212 CFR 601.90, commonly known as the
‘Animal Rule’ which allows for the use of animal data to
support efficacy claims of a human vaccine. Because
animal models that reflect human disease are a requisite
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for licensure under this rule, great efforts are being made
to develop suitable animal models, especially nonhuman
primate models for a variety of diseases.
One animal model that shows promise for animal rule
studies with a number of viruses is the common marmo-
set, as described by Carrion and Patterson. These small
new world primates are said to be especially appropriate
for high containment studies both because of space con-
straints within those laboratories, and also because they
have an immune system similar to that of humans. As the
authors discuss, marmosets have now been tested as
models for hemorrhagic fever viruses requiring biosafety
level 4 containment, such as the arenaviruses Lassa and
Junin viruses, and the filoviruses EBOV and Marburg
virus. Marmoset models have also been developed for the
respiratory disease caused by SARS-coronavirus, and for
encephalitis caused by infection with eastern equine
encephalitis virus (EEEV).
Development of larger nonhuman primate models for
EEEV as well as Venezuelan (VEEV), and western
equine encephalitis viruses are discussed by Dupuy
and Reed. Most studies to date have used either rhesus
or cynomolgus macaques as models for disease that occurs
after aerosol exposure to these viruses. Although the
infectious dose in these models is relatively high and
more studies on pathophysiology will be needed, the
macaque models for these three alphaviruses hold much
promise given that the clinical symptoms closely
resemble human disease and neutralizing antibody titers
could be used as a correlate of protection. All three of
these alphaviruses are considered to be biowarfare agents,
and evidence exists for the past weaponization of VEEV
by several countries [7]. For biodefense, a vaccine that
would prevent disease after aerosol exposure to virus is
required, but developing an animal model mimicking a
human disease resulting from an unnatural exposure
route is especially challenging and relies mostly on obser-
vations from the less than 200 laboratory infections with
VEEV that resulted in two deaths [8].
Conclusions
Viral zoonoses are an important cause of human morbid-
ity and mortality. As more information has accumulated,
it has become obvious that animal health and human
health cannot be separated. Animals not only function to
maintain and amplify pathogenic viruses in nature, but
cross-species transmission can occur for members of
numerous viral families and such events have in the past,
and likely will continue in the future, to give rise to new
veterinary or human disease agents. Vaccination of wild-
life or domesticated animals can be effective for prevent-
ing some viral diseases of humans, but not all. Vector or
host control measures are often also required, and for
certain viruses, it is simply not feasible to vaccinate the
wide variety of hosts that harbor them in nature. Like-
wise, eradication of zoonotic viruses through vaccination,
while a worthy goal, will be possible for only a few viruses
and will depend on an ability to completely control the
disease through mass vaccinations. The possibility that
the biological niche of an eradicated virus will be filled by
another pathogen must also be considered. The devel-
opment of modern vaccines is costly and obtaining ef-
ficacy data for some agents may prove to be impossible
due to limited case numbers. Economic aid and alterna-
tive licensure paths will likely be required to provide
vaccines for many viral pathogens. Finally, animals are
now playing another important role in vaccine develop-
ment efforts by serving as efficacy models that will
provide data that potentially can be used to license safe
and effective human vaccines. The one health concept
for humans and animals is clearly here to stay.
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